The Challenge

Currently, there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and very few treatments approved for use against COVID-19. 

To effectively address COVID-19, the world will require multiple prevention and treatment options. The CTA is working to coordinate R&D efforts to help remove barriers to drug development and scale up interventions that can be used as prophylactics or to treat mild and moderate forms of COVID-19.  

A scientist dressed in protective gear looks in a microscope.
Photo by Shutterstock

…Investing now, at scale, at risk and as a collective global effort is vital if we are to change the course of this epidemic. We welcome others to join us in this effort.

-Dr. Jeremy Farrar, Director of Wellcome
Boxes of medication on a conveyor belt.
Photo by Shutterstock

The Vision

A Global Coordinated Effort

The CTA coordinates with the Therapeutics Partnership of the Access to COVID-19 Tools Accelerator (ACT-A) working with the World Health Organization, the global research community, governments, private sector organizations, and global regulators to help accelerate development of safe, effective and accessible drugs.

End-to-End Approach

The CTA has a truly end-to-end focus, from drug pipeline development through to manufacturing and scale up. By sharing knowledge, coordinating investments and pooling resources, we are helping to accelerate research. 

Fast and Flexible Funding

The CTA’s governance model allows participating organizations to provide fast and flexible funding to help remove bottlenecks in the drug development and scale-up process. 

Equitable Access

The CTA puts equity at the core of its approach. Coordinating organizations are committed to ensuring that the innovations supported are available and affordable in low-resource settings. 


We can combat COVID-19 together. Sharing knowledge and resources across governments, the private sector, academia and philanthropy can accelerate the timeline for bringing treatments to market.

Two scientists dressed in protective gear examine a sample.
Photo by Getty Images

Featured Collaborations

Proprietary libraries of molecular compounds

Many companies have agreed to share their proprietary libraries of molecular compounds that already have some degree of safety and activity data to quickly screen them for potential use against COVID-19. Successful hits could move into in vivo trials in a rapid timeframe. 

Research networks and existing partnerships

Existing collaborative networks of researchers and academic institutions are transitioning their work to support rapid assessments of therapeutics identified by the CTA. These networks of clinical and academic researchers are prioritizing their activities in support of testing COVID-19 therapeutics. 

Material supply and scale up

The CTA is working with manufacturers of active pharmaceutical ingredients and finished therapeutic products so that there will be dedicated capacity to manufacture and supply any promising therapeutic candidates for use in low- and middle-income countries. 

Progress and Action

Robotic arm in a lab reaching for a tray of samples.
Photo by Shutterstock

Investments Made

We can combat COVID-19 together. The CTA has made investments in the evaluation of already approved drugs and is creating platforms for studying new therapeutics as they are advanced. To see CTA investments to date, select the link below. 

Explore investments made


Get answers to key questions about the CTA’s work and approach. 

Learn more
Unlabeled circular medicine tablets scattered on a table.
Photo by Hal Gatewood on Unsplash